Istituto Romagnolo per lo studio dei Tumori "Dino Amadori"

The trials here

What the 11 trials at this site are about, from their registry records.

Conditions

• Colorectal cancer3 trials
• Lung cancer2 trials
• Melanoma2 trials
• Myeloproliferative neoplasms2 trials
• Chronic lymphocytic leukaemia1 trial
• Gastric and oesophageal cancer1 trial
• Metastatic breast cancer1 trial
• Myelodysplastic syndromes1 trial
• Pancreatic cancer1 trial

Phase

• Phase 1/24 trials
• Phase 34 trials
• Phase 22 trials
• Phase 11 trial

Status

• Terminated3 trials
• Active, not recruiting2 trials
• Completed2 trials
• Recruiting2 trials
• Not yet recruiting1 trial
• Suspended1 trial

Lead sponsor

• Incyte Corporation3 trials
• Gruppo Oncologico del Nord-Ovest2 trials
• Anaveon AG1 trial
• BioNTech SE1 trial
• EQRx, Inc.1 trial
• and 3 more

Running trials

• Recruiting

  Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer

  NCT07389265· Phase 3· University of Campania Luigi Vanvitelli· Source

  Contact: Alessandro Passardi (principal investigator)

• Recruiting

  A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

  NCT07070232· Phase 1/2· BioNTech SE· Source

• Active, not recruiting

  A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients

  NCT06879717· Phase 1/2· iOnctura· Source

• Recruiting

  FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.

  NCT06733038· Phase 3· Gruppo Oncologico del Nord-Ovest· Source

  Contact: Alessandro Passardi, MD

• Active, not recruiting

  Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

  NCT04279847· Phase 1· Incyte Corporation· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer2 recruiting
• Gastric and oesophageal cancer1 recruiting
• Lung cancer1 recruiting
• Melanoma1 recruiting

Closed trials

• Completed

  A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).

  NCT05578872· Phase 1/2· Anaveon AG· Source

• Terminated

  A Study of Lerociclib in Participants With Advanced Breast Cancer

  NCT05085002· Phase 2· EQRx, Inc.· Source

• Terminated

  A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)

  NCT04809467· Phase 1/2· Incyte Corporation· Source

• Terminated

  To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

  NCT04551066· Phase 3· Incyte Corporation· Source

• Completed

  A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment

  NCT04083235· Phase 3· Ipsen· Source